Shuttle Pharmaceuticals Holdings Inc (SHPH)

$0.66 -0.02 (-3.29%)
Market Cap 3.80M
Revenue (ttm) 0.00
Net Income (ttm) -11.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 151,900
Avg Vol 1,064,074
Day's Range N/A - N/A
Shares Out 5.59M
Stochastic %K 9%
Beta 0.38
Analysts Strong Buy
Price Target N/A

Company Profile

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HD...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 240 403 4212
Address:
401 Professional Drive, Suite 260, Gaithersburg, United States
MorenitaScorp
MorenitaScorp May. 12 at 1:28 PM
$SHPH ⌚️
0 · Reply
Marko1984
Marko1984 May. 8 at 7:19 PM
$SHPH why does this Keep falling!?
2 · Reply
focafoca99
focafoca99 May. 7 at 9:52 PM
$SHPH merged with United Dogecoin Inc., completing its acquisition and becoming a wholly owned subsidiary of the acquirer.
0 · Reply
CantAffordMe
CantAffordMe May. 7 at 2:52 PM
$SHPH in the toilet it belongs
0 · Reply
CantAffordMe
CantAffordMe May. 7 at 2:15 PM
$SHPH Flush thus terd
0 · Reply
321rip
321rip May. 6 at 12:50 PM
$SHPH check out $SMX, yest. ended selling
0 · Reply
CantAffordMe
CantAffordMe May. 6 at 11:22 AM
$SHPH this terd about to blast out the ass
0 · Reply
Stocksgoogle
Stocksgoogle May. 6 at 10:24 AM
$SHPH patience is the key for some of the tickers , this explodes 2-4 times in a year and depending on the entry point, you can make a whole lot, timing the entry at right point is the key and not many have mastered that so key is take profit whenever you can or know when to cut loss short, leave it to you all intelligent people out there. DYOR GLTA
0 · Reply
j_joss420
j_joss420 May. 6 at 12:24 AM
$SHPH MMMMM OK!!
0 · Reply
FinacialSuicide
FinacialSuicide May. 5 at 11:10 PM
$SHPH this is ripped by shorts! Might continue to bleed short term but has a positive future ahead !
0 · Reply
Latest News on SHPH
E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner

May 7, 2026, 2:02 PM EDT - 5 days ago

E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner

United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation

May 1, 2026, 8:41 AM EDT - 12 days ago

United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation

Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner

Apr 30, 2026, 4:05 PM EDT - 12 days ago

Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner

RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Mar 27, 2026, 8:00 AM EDT - 6 weeks ago

RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Mar 26, 2026, 4:05 PM EDT - 6 weeks ago

Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering

Mar 12, 2026, 8:30 AM EDT - 2 months ago

E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering

Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Mar 6, 2026, 8:00 AM EST - 2 months ago

Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

Jan 13, 2026, 4:00 PM EST - 4 months ago

Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

Shuttle Pharmaceuticals Acquires AI Health Platform

Nov 21, 2025, 9:30 AM EST - 6 months ago

Shuttle Pharmaceuticals Acquires AI Health Platform

Shuttle Pharmaceuticals files to sell 625,156 shares of common stock for holders

2025-11-18T22:05:15.000Z - 6 months ago

Shuttle Pharmaceuticals files to sell 625,156 shares of common stock for holders

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Nov 3, 2025, 7:00 AM EST - 6 months ago

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Oct 22, 2025, 10:00 AM EDT - 7 months ago

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Oct 22, 2025, 7:00 AM EDT - 7 months ago

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Oct 21, 2025, 5:55 PM EDT - 7 months ago

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Oct 21, 2025, 4:05 PM EDT - 7 months ago

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Shuttle Pharmaceuticals announces extension of LOI with Molecule.ai

2025-10-10T14:25:15.000Z - 7 months ago

Shuttle Pharmaceuticals announces extension of LOI with Molecule.ai

Shuttle Executes LOI with Molecule.ai

Oct 10, 2025, 10:20 AM EDT - 7 months ago

Shuttle Executes LOI with Molecule.ai

Shuttle Pharmaceuticals to acquire Molecule.ai for $10M

2025-10-09T20:25:12.000Z - 7 months ago

Shuttle Pharmaceuticals to acquire Molecule.ai for $10M

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Oct 9, 2025, 4:15 PM EDT - 7 months ago

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Aug 14, 2025, 4:05 PM EDT - 9 months ago

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Shuttle Pharmaceuticals files to sell 1.18M shares of common stock for holders

2025-08-05T10:16:04.000Z - 10 months ago

Shuttle Pharmaceuticals files to sell 1.18M shares of common stock for holders

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Jun 24, 2025, 4:10 PM EDT - 11 months ago

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Jun 20, 2025, 3:55 PM EDT - 11 months ago

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharmaceuticals Holdings Inc trading halted, news pending

2025-06-13T23:50:22.000Z - 11 months ago

Shuttle Pharmaceuticals Holdings Inc trading halted, news pending

Shuttle Pharmaceuticals says reverse stock split to become effective June 16

2025-06-12T16:05:29.000Z - 11 months ago

Shuttle Pharmaceuticals says reverse stock split to become effective June 16

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Jun 12, 2025, 12:00 PM EDT - 11 months ago

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Shuttle Pharmaceuticals announces 25-for-1 proposed reverse stock split

2025-06-12T12:45:38.000Z - 11 months ago

Shuttle Pharmaceuticals announces 25-for-1 proposed reverse stock split

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Jun 12, 2025, 8:30 AM EDT - 11 months ago

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Shuttle Pharmaceuticals appoints George Scorsis as chairman

2025-06-04T20:10:45.000Z - 1 year ago

Shuttle Pharmaceuticals appoints George Scorsis as chairman

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Jun 4, 2025, 4:01 PM EDT - 1 year ago

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Shuttle Pharma Ropidoxuridine Phase 2 trial nears 50% enrollment

2025-05-15T20:50:26.000Z - 1 year ago

Shuttle Pharma Ropidoxuridine Phase 2 trial nears 50% enrollment

Shuttle Pharma Provides Corporate Update

May 15, 2025, 4:45 PM EDT - 1 year ago

Shuttle Pharma Provides Corporate Update

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

May 8, 2025, 4:01 PM EDT - 1 year ago

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 21, 2025, 4:15 PM EDT - 1 year ago

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Shuttle Pharmaceuticals files provisional patent application with USPTO

2025-04-10T20:10:54.000Z - 1 year ago

Shuttle Pharmaceuticals files provisional patent application with USPTO

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Apr 10, 2025, 4:01 PM EDT - 1 year ago

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Mar 13, 2025, 4:10 PM EDT - 1 year ago

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Shuttle Pharmaceuticals prices 19.17M shares at 30c per share in public offering

2025-03-12T13:30:38.000Z - 1 year ago

Shuttle Pharmaceuticals prices 19.17M shares at 30c per share in public offering

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Mar 12, 2025, 9:24 AM EDT - 1 year ago

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO

2025-03-12T10:25:28.000Z - 1 year ago

Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Mar 12, 2025, 6:20 AM EDT - 1 year ago

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Feb 26, 2025, 10:45 AM EST - 1 year ago

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Shuttle reaches milestone in enrollment for Phase 2 trial of Ropidoxuridine

2025-01-21T14:15:45.000Z - 1 year ago

Shuttle reaches milestone in enrollment for Phase 2 trial of Ropidoxuridine

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 7, 2025, 9:00 AM EST - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF

2024-12-19T14:11:32.000Z - 1 year ago

Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF

Shuttle first patient enrollment, dosing in Phase 2 Ropidoxuridine line

2024-11-26T14:06:10.000Z - 1 year ago

Shuttle first patient enrollment, dosing in Phase 2 Ropidoxuridine line

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Nov 26, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Nov 13, 2024, 5:00 PM EST - 1 year ago

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share

2024-10-30T01:10:10.000Z - 1 year ago

Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 29, 2024, 9:05 PM EDT - 1 year ago

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine

2024-10-29T13:05:45.000Z - 1 year ago

Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 28, 2024, 4:05 PM EDT - 1 year ago

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 16, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Sep 4, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Aug 26, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Aug 14, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Jun 18, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 22, 2024, 4:15 PM EDT - 2 years ago

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Shuttle Pharma Provides First Quarter 2024 Corporate Update

May 14, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 23, 2024, 4:15 PM EDT - 2 years ago

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Apr 3, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Mar 22, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Mar 5, 2024, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Feb 13, 2024, 8:00 AM EST - 2 years ago

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 23, 2024, 4:30 PM EST - 2 years ago

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jan 8, 2024, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

MorenitaScorp
MorenitaScorp May. 12 at 1:28 PM
$SHPH ⌚️
0 · Reply
Marko1984
Marko1984 May. 8 at 7:19 PM
$SHPH why does this Keep falling!?
2 · Reply
focafoca99
focafoca99 May. 7 at 9:52 PM
$SHPH merged with United Dogecoin Inc., completing its acquisition and becoming a wholly owned subsidiary of the acquirer.
0 · Reply
CantAffordMe
CantAffordMe May. 7 at 2:52 PM
$SHPH in the toilet it belongs
0 · Reply
CantAffordMe
CantAffordMe May. 7 at 2:15 PM
$SHPH Flush thus terd
0 · Reply
321rip
321rip May. 6 at 12:50 PM
$SHPH check out $SMX, yest. ended selling
0 · Reply
CantAffordMe
CantAffordMe May. 6 at 11:22 AM
$SHPH this terd about to blast out the ass
0 · Reply
Stocksgoogle
Stocksgoogle May. 6 at 10:24 AM
$SHPH patience is the key for some of the tickers , this explodes 2-4 times in a year and depending on the entry point, you can make a whole lot, timing the entry at right point is the key and not many have mastered that so key is take profit whenever you can or know when to cut loss short, leave it to you all intelligent people out there. DYOR GLTA
0 · Reply
j_joss420
j_joss420 May. 6 at 12:24 AM
$SHPH MMMMM OK!!
0 · Reply
FinacialSuicide
FinacialSuicide May. 5 at 11:10 PM
$SHPH this is ripped by shorts! Might continue to bleed short term but has a positive future ahead !
0 · Reply
Stocksgoogle
Stocksgoogle May. 5 at 7:43 PM
$SHPH this one is on and around the same price since morning but this sort of stock when goes up it takes more than 50% jump normally up or down so here be sure only use what you can afford to lose DYOR GLTA
0 · Reply
321rip
321rip May. 5 at 4:06 PM
$SHPH set to blast thru yest. .95 HI like a bull on steroids
0 · Reply
321rip
321rip May. 5 at 2:57 AM
$SHPH nice 70% p/b of pre mkt HI
0 · Reply
Luckytoo8
Luckytoo8 May. 5 at 1:25 AM
$SHPH ...the Company and Merger Sub will become the debts, liabilities and duties of the Surviving Corporation. The Closing is expected to occur on Monday, May 4, 2026 (the “Closing Date”).
0 · Reply
FinacialSuicide
FinacialSuicide May. 5 at 12:27 AM
$SHPH 4.5 M shares shorted today!
0 · Reply
realditzy
realditzy May. 4 at 8:46 PM
$SHPH
0 · Reply
InvestingSpaceman
InvestingSpaceman May. 4 at 8:38 PM
$GMEX $SHPH $FSTR %_
0 · Reply
321rip
321rip May. 4 at 8:29 PM
$SHPH multi day runner
0 · Reply
InvestingSpaceman
InvestingSpaceman May. 4 at 7:41 PM
$ARKR $SHPH $WYY $REPL on the move!
0 · Reply
Game_Day
Game_Day May. 4 at 5:37 PM
CABA (AM ALERT) Trending 🔥 $ATLX $CABA $SHPH
0 · Reply
CantAffordMe
CantAffordMe May. 4 at 5:31 PM
$SHPH Lol back down the shitter this goes
0 · Reply
10xorbust
10xorbust May. 4 at 3:55 PM
$ATLX $CABA $SHPH I wouldn’t day a single share of CABA. This is a hold for me. There’s potential mega money here. This thing absolutely has a potential to 10X or 20 X.
1 · Reply